Continuous Hemodiafiltration in Pediatric Critical Care Patients

• Published in: Therapeutic apheresis and dialysis Vol. 8; no. 5; pp. 390 - 397
• Main Authors: Shiga, Hidetoshi, Hirasawa, Hiroyuki, Oda, Shigeto, Matsuda, Kenichi, Ueno, Hirokazu, Nakamura, Masataka
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Science Pty 01.10.2004
• Subjects: Adolescent; Anticoagulants; Anticoagulants - administration & dosage; Body Size - drug effects; Body Size - physiology; Body Temperature - drug effects; Body Temperature - physiology; Child; Child, Preschool; Continuous hemodiafiltration; Critical Care; Critical Illness; Female; Guanidines - administration & dosage; Hemodiafiltration - methods; Hemodynamics; Humans; Hypothermia; Infant; Infant, Newborn; Male; Pediatric patients; Pediatrics - methods
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/j.1526-0968.2004.00174.x

:  Continuous hemodiafiltration (CHDF) is an essential procedure in critical care. However, application of this therapy to pediatric patients is associated with several problems derived from their smaller body size and weight compared with adults. We have successfully conducted CHDF in pediatric patients including newborns by taking such problems into consideration and carefully coping with them. The present study consisted of 60 pediatric patients treated with CHDF. Clinical efficacy and safety of CHDF in pediatric patients were assessed in these patients by reviewing patient clinical records. The 60 patients treated with CHDF included 27 males and 33 females. Their body weight ranged from 700 g to 53.0 kg. The mean CHDF duration was 6.80 ± 6.94 days. Blood access was provided in a veno‐venous mode in 42 patients, and an arterio‐venous mode in 18 patients. Of the 60 pediatric patients receiving CHDF, 31 patients survived without serious complications, achieving a survival rate of 51.7%. Successful CHDF in pediatric patients was achieved by careful and exact execution of the following countermeasures to overcome problems specific to application of this therapy to pediatric patients: minimization of the priming volume; use of colloid solutions or whole blood as priming solution; maintaining secure blood access; selection of an appropriate anticoagulant; temperature control of both the patient's body and components of the hemofiltration circuit. In pediatric critical care, CHDF is safely applicable to the critically ill and expected to produce a wide spectrum of clinical efficacy just as in adults.